linjc16/ctgov huggingface dataset:
Uterocervical Angle in the Pregnancy Termination of Multiparous Women

Study Overview
=================
Brief Summary
-----------------
To evaluate the uterocervical angle (UCA) in the prediction of second trimester termination success of multiparous women.

Detailed Description
-----------------
Medical termination of pregnancy is a common procedure in obstetrics. In recent years, uterocervical angle (UCA) emerged as a new ultrasound parameter in the prediction of labor. Dziadosz et al concluded that the performance of UCA was even better than the cervical length in their cohort. A wide UCA during second trimester shown to have an increased risk of preterm labor and narrow angle was less likely to have labor. The investigators are aimed to investigate predictive role of both cervical length and UCA in the termination of second trimester pregnancy.The investigators focused on multiparous women who are taking Foley baloon for the cervical preparation and aim to measure their UCA.

Official Title
-----------------
Uterocervical Angle in the Termination of Second Trimester Pregnancy in Multiparous Women

Conditions
-----------------
Medical; Abortion, Fetus, Second Trimester Abortion

Intervention / Treatment
-----------------
* Other: uterocervical angle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: multiparous singleton pregnancy no previous systemic illnesses Exclusion Criteria: abnormal Pap smear history of dilatation and curettage (D&C) history of LEEP and cervical conization

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Medical abortion<br>150 singleton multiparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were multiparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor. | Other: uterocervical angle<br>* the angle between cervical canal and anterior uterine wall is measured sonographically.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| uterocervical angle | the angle between the cervical canal and anterior uterine wall | 1 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
uterocervical angle, multiparous
MRI Study of the Gastric Insufflation After High-flow Nasal Oxygen (HFNO)

Study Overview
=================
Brief Summary
-----------------
HFNO CAN BE USED AS A PREOXYGENATION TECHNIQUE BUT IS IT A SAFE TECHNIQUE IN TERMS OF GASTRIC INSUFFLATION?

Detailed Description
-----------------
The objective of this study is to evaluate by MRI whether the stomach is insufflated during HFNO use in healthy volunteers.

Official Title
-----------------
MRI Study of the Gastric Insufflation After High-flow Nasal Oxygen (HFNO)

Conditions
-----------------
MRI

Intervention / Treatment
-----------------
* Device: HFNO for 5 min


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults Volunteers Exclusion Criteria: Pregnancy Claustrophobia Gastric surgery Gastric pathology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: HFNO for 5 min|1st basic MRI then HFNO for 5 min with mouth closed breathing and 2nd MRI. Analysis of the surface of the gastric antrum.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of the antero-posterior and cranio-caudal diameters of the gastric antrum | surface of the gastric antrum | through study completion, an average of 1 year |
Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.

Study Overview
=================
Brief Summary
-----------------
Fungal infections have increased over the last two decades, largely because of the increasing size of the population at risk, including patients who are immunocompromised, broad-spectrum antibiotics and intravascular catheter users. Essential oils and other extracts of plants have evoked interest as sources of natural products. They have been shown to possess antibacterial, antifungal, antiviral, insecticidal and antioxidant properties. To the best of our knowledge, no study has examined the efficacy of cumin seed extract on relieving vulvovaginal candidiasis in vivo.

Official Title
-----------------
Randomized Clinical Trial for Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.

Conditions
-----------------
Infection, Fungal

Intervention / Treatment
-----------------
* Drug: Cumin seed extract
* Drug: clotrimazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women were 18-49 years old and were married; They had not used antibiotics, immunosuppressive drugs, or vaginal drugs 14 days before the study; They did not suffer from trichomonal vaginitis, bacterial vaginitis, or cervicitis based on direct smear; Candidiasis culture was in agreement with clinical symptoms and patient's complaints. Exclusion Criteria: Pregnant and lactating women; Those who had abnormal uterine bleeding; Women with diabetes or autoimmune diseases; Women refuse to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cumin seed extract<br>Group A (study group) will receive Cumin seed extract vaginal suppositories once daily for 7 days. | Drug: Cumin seed extract<br>* patients will receive the drug in suppository form<br>|
| Active Comparator: clotrimazole<br>Group B will receive conventional clotrimazole vaginal suppositories once daily for 7 days. | Drug: clotrimazole<br>* patients will receive the drug in suppository form<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of patients with complete cure | cure is defines as absence of symptoms | one week |
Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
This observational study will collect prospective data on the safety and tolerability of Xeloda in patients with advanced gastric cancer from every day clinical practice. Documentation of treatment for each patient is to continue until the end of treatment per oncologist's assessment.

Official Title
-----------------
NIS Xeloda in Gastric Cancer

Conditions
-----------------
Gastric Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged >/=18 years, with metastatic gastric cancer who are available for prospective documentation of their treatment (first-line chemotherapy) Informed consent Exclusion Criteria: Contraindications to Xeloda per the Summary of Product Characteristics (SmPC)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival |  | Up to 4 years | 
| Safety and tolerability: incidence and nature of adverse drug reactions |  | Up to 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with modifications in Xeloda dosing |  | Up to 4 years | 
| Average duration of treatment |  | Up to 4 years | 
| Number of modifications in chosen regimen combination therapy |  | Up to 4 years | 
| Incidence and nature of dose interruptions |  | Up to 4 years |
Development of Normative Ultrasound Databases of Tongue Surface Configuration

Study Overview
=================
Brief Summary
-----------------
Our past ultrasound research has indicated a need for baseline normative tongue data against which to compare our disordered speech populations. Subjects with normal speech and hearing who represent different ages and sexes, will be studied with respect to tongue shape and movement patterns. Recently developed parameters such as curve fitting, curve averaging, and polar coordinates will be used to create baseline data categories. In addition, new parameters and improved instruments will be developed as previously to produce a data base which can be used across disciplines.

Detailed Description
-----------------
Our past ultrasound research has indicated a need for baseline normative tongue data against which to compare our disordered speech populations. Subjects with normal speech and hearing who represent different ages and sexes, will be studied with respect to tongue shape and movement patterns. Recently developed parameters such as curve fitting, curve averaging, and polar coordinates will be used to create baseline data categories. In addition, new parameters and improved instruments will be developed as previously to produce a data base which can be used across disciplines.

Official Title
-----------------
Development of Normative Ultrasound Databases of Tongue Surface Configuration

Conditions
-----------------
Healthy, Speech Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Healthy normal subjects. No reconstructive tongue surgery. No radiation for head and neck malignancy.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Baseline Data, Curve Averaging, Curve Fitting, Movement Patterns, Normative Data, Polar Distribution, Tongue, Tongue Shape, Ultrasound
MRI Development for Radiotherapy Planning and Delivery in Non-Patient Volunteers

Study Overview
=================
Brief Summary
-----------------
Non-patient volunteers will be scanned on the MR-Linac and MRSIM to facilitate the development, optimisation and validation of MRI protocols at The Christie NHS Foundation Trust.

Official Title
-----------------
MRI Development for Radiotherapy Planning and Delivery in Non-Patient Volunteers

Conditions
-----------------
Focus of the Study is MRI Sequence Development

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing and able to provide written consent Volunteers must undergo and satisfy MRI safety screening Volunteers must be ≥ 16 years of age Participants must agree to registration as a non-patient in CWP (the Trust's Electronic Health Record - EHR- system) and have their MRIs read and reported for incidental findings by a clinical radiologist Exclusion Criteria: Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form Unable to tolerate MRI scan Known Pregnancy Known or suspected pathology in body region to be scanned Member of study team

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Developed and optimised of MRI scanning sequences for use in clinical radiotherapy practice in MR guided radiotherapy | on-going development of MRI protocols to be released for clinical use | Through study completion - up to 5 years |
Inherited CAncer REgistry

Study Overview
=================
Brief Summary
-----------------
The purpose of the Inherited CAncer REgistry (ICARE) Initiative is to provide individuals interested in participating in studies focused on inherited cancer predisposition the opportunity to enroll in a research registry. Efforts through the registry include, but are not limited to, contribution of data to observational studies, targeted gene-specific studies, and education and outreach efforts for both participants and recruiting healthcare providers. Participants are given the opportunity to learn about and participate in other efforts for which they may be eligible. All participants and recruiting healthcare providers receive educational newsletters twice per year which contain research and clinical updates in the field of cancer genetics. Providers who recruit patients can also access monthly web-based genetics case conferences which focus on different topics each month and are generally attended by a guest expert who provides background information on the topic as well as comments on the case presentations. Participation in ICARE involves completion of an informed consent form, baseline questionnaire, follow-up questionnaires every two years, and medical record/tumor releases, as applicable. There is no cost to participate and all correspondence can be facilitated through phone, email, or mail. Enrollment can be completed either through a traditional paper-based consenting method (i.e. postal mail) or through the online enrollment option available on the ICARE website (InheritedCancer.net). If you are a patient interested in learning more or a provider interested in recruiting to ICARE, please visit our website where you may complete an online contact form requesting a study team member contact you.

Official Title
-----------------
Inherited CAncer REgistry (ICARE) Initiative

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Able and willing to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Establish and maintain a registry of individuals who are interested in participating in studies of the genetics of cancer and other related investigations. |  | Up to 100 years |
Biological Markers to Identify Early Sepsis and Acute Lung Injury

Study Overview
=================
Brief Summary
-----------------
There are no clear markers to identify sepsis and acute lung injury at early stage in clinical settings which would result in improved survival of the patients. In collaboration with the research team led by Dr. Zhang at St. Michael's Hospital, Toronto, we have initiated a pilot study looking for biological markers to detect severe sepsis and ARDS. We have found that human neutrophils peptides (a-defensins), certain coagulation variables and cytokine levels are very sensitive markers to differentiate severe sepsis, ARDS from cardiovascular diseases in ICU patients. These findings may provide valuable information for therapeutic guideline in clinical practice. The present study will focus on testing 'biological markers' to identify patients with sepsis and acute lung injury. We will examine the roles of three components of markers including inflammation, neutrophil activation and coagulation. We are hoping that this proposed translational research will help develop novel therapeutic strategy in sepsis and acute lung injury patients.

Conditions
-----------------
Sepsis, Acute Lung Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet diagnostic criteria of ≧2 SIRS or acute lung injury. Get agreement of patient's attending physician and inform consent form patient or family. Exclusion Criteria: Use Antibiotics over 24 hrs（only SIRS group）. Active bleeding. Pregnancy. Active Cancer (refer to malignancy which is recently diagnosed, under treatment, or relapsed) VS or Subject or Family refuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The present study will focus on testing 'biological markers' to identify patients with sepsis and acute lung injury in early stage. |  | 72 hrs | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biological markers, sepsis, acute lung injury
Adherence to Gastro-protection in Non-steroidal Anti-inflammatory Drug (NSAID) Using Patients

Study Overview
=================
Brief Summary
-----------------
Prospective multicentric study to evaluate the compliance of gastroprotective treatment in NSAID patients at risk of GI complications. Secondary objectives: To identify the factors associated to treatment compliance (both NSAID and PPI), to evaluate the relationship between compliance and NSAID-associated GI events

Official Title
-----------------
Compliance of Gastroprotection Treatment in the Prevention of Gastrointestinal Risk in Non-Steroidal Anti-inflammatory Drug (NSAID) Using Patients

Conditions
-----------------
Compliance, Gastroprotector Therapy, Risk Factors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent Patients consulting to the specialized care clinics who have been prescribed NSAID and gastroprotection for at least 15 days following standard clinical practice. Exclusion Criteria: Any gastroprotective treatment prescribed for other condition than NSAID-related gastrointestinal event prevention

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>NSAID patients with risk factors treated with gastroprotective drugs | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence to gastroprotection treatment |  | End of follow-up (3-5 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify factors associated with treatment compliance |  | End of follow-up | 
| Evaluate the relationship among GI events and treatment compliance |  | End of follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Compliance, gastroprotector therapy, NSAID, risk factors
Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients

Study Overview
=================
Brief Summary
-----------------
Non-commercial depersonalized multi-centered registry study on analysis of chronic non-infectious diseases dynamics after SARS-CoV-2 infection in adults.

Detailed Description
-----------------
Non-commercial depersonalized multi-centered registry study on analysis of chronic non-infectious diseases dynamics after SARS-CoV-2 infection in cohort of Russian adult patients. Retrospective analysis of medical histories and outcomes in adults with pre-existing conditions after SARS-CoV-2 infection and prospective monitoring of health status during 3, 6 and 12 months after discharge. Comorbidities worsening risk factors measuring through evaluation of range of indicators such as dynamics of diabetes, CKD, COPD, bronchial astma, incidence of hypertonic crises, vascular events and others.

Official Title
-----------------
Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients

Conditions
-----------------
Covid19, SARS-CoV-2 Infection, Pneumonia, Copd, CKD, Cardiac Event, Overweight and Obesity, Cardiovascular Diseases, Diabetes, Hypertension, Coronary Heart Disease

Intervention / Treatment
-----------------
* Other: non-interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspected or confirmed COVID-19. Exclusion Criteria: Refuse to be involved in study; Age under 18 years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| inpatients<br>Patients treated from COVID-19 in hospital | Other: non-interventional<br>* Interview on health conditions<br>|
| outpatients<br>Patients treated from COVID-19 at home | Other: non-interventional<br>* Interview on health conditions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of non-infectious diseases | percentage of patients with non-infectious diseases relating to overall number of patients registered in study | 12 month since a moment of request of medical help | 
| severity of COVID-19 depending on pre-existing diseases | correlation between number of patients with COVID-19 of various severity and number of pre-existing conditions and their severity among these groups | 12 month since a moment of request of medical help | 
| disability registration / change of disability status | Registration of disability or change of disability status | 12 month since a moment of request of medical help | 
| rate of letal outcomes | rate of deaths among registered participants | 12 month since a moment of request of medical help | 
| rate of letal outcomes depending on pre-existing disease | correlation between number of deaths and pre-existing diseases | 12 month since a moment of request of medical help |